HRP20110899T1 - Protutumorsko cjepivo dobiveno iz normalnih, kemijski modificiranih stanica cd4+ - Google Patents
Protutumorsko cjepivo dobiveno iz normalnih, kemijski modificiranih stanica cd4+ Download PDFInfo
- Publication number
- HRP20110899T1 HRP20110899T1 HR20110899T HRP20110899T HRP20110899T1 HR P20110899 T1 HRP20110899 T1 HR P20110899T1 HR 20110899 T HR20110899 T HR 20110899T HR P20110899 T HRP20110899 T HR P20110899T HR P20110899 T1 HRP20110899 T1 HR P20110899T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- lymphocytes
- cells
- antigen
- antigens
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims 3
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 claims abstract 10
- 102000036639 antigens Human genes 0.000 claims abstract 10
- 108091007433 antigens Proteins 0.000 claims abstract 10
- 210000004698 lymphocyte Anatomy 0.000 claims abstract 10
- 238000000034 method Methods 0.000 claims abstract 9
- 210000004027 cell Anatomy 0.000 claims abstract 6
- 210000004443 dendritic cell Anatomy 0.000 claims abstract 4
- 230000035755 proliferation Effects 0.000 claims abstract 4
- 230000035131 DNA demethylation Effects 0.000 claims abstract 3
- 230000006195 histone acetylation Effects 0.000 claims abstract 3
- 230000002062 proliferating effect Effects 0.000 claims abstract 3
- 230000004936 stimulating effect Effects 0.000 claims abstract 3
- 230000008105 immune reaction Effects 0.000 claims abstract 2
- 239000000126 substance Substances 0.000 claims abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 3
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 1
- 230000007067 DNA methylation Effects 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000006197 histone deacetylation Effects 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 231100000405 induce cancer Toxicity 0.000 abstract 1
- 230000002381 testicular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1121—Dendritic cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Postupak priprave antigenski prezentirajućeg pripravka obogaćenog stanicama CD4+, naznačen time što se sastoji u stimuliranju proliferacije normalnih neaktiviranih limfoidnih stanica uz pomoć normalnih zrelih dendritičkih stanica koje ne sadrže antigene na koje treba usmjeriti imunosnu reakciju koju će se inducirati, te u kemijskoj obradi proliferirajućih stanica sredstvima koja induciraju demetiliranje DNA ili acetiliranje histona kako bi se induciralo ekspresiju antigena raka odnosno testisa. Patent sadrži još 14 patentnih zahtjeva.
Claims (15)
1. Postupak priprave antigenski prezentirajućeg pripravka obogaćenog stanicama CD4+, naznačen time što se sastoji u stimuliranju proliferacije normalnih neaktiviranih limfoidnih stanica uz pomoć normalnih zrelih dendritičkih stanica koje ne sadrže antigene na koje treba usmjeriti imunosnu reakciju koju će se inducirati, te u kemijskoj obradi proliferirajućih stanica sredstvima koja induciraju demetiliranje DNA ili acetiliranje histona kako bi se induciralo ekspresiju antigena raka odnosno testisa.
2. Postupak u skladu s patentnim zahtjevom 1, naznačen time što su limfoidne stanice limfociti iz periferne krvi, izolrani iz heterologne ili autologne krvi.
3. Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se antigene inducira tijekom logaritamske faze proliferacije.
4. Postupak priprave citotoksičnog pripravka, naznačen time što se sastoji u pripravi antigenski prezentirajućeg pripravka postupkom u skladu s bilo kojim od patentnih zahtjeva 1 to 3, te u upotrebi antigenski prezentirajućeg pripravka u aktivaciji T-limfocita, čime se dobiva citotoksični pripravak koji sadrži tumorski specifične citotoksične T-limfocite CD8+.
5. Postupak u skladu s patentnim zahtjevom 4, naznačen time što se broj T-limfocita povećava nakon aktivacije uz pomoć zrelih dendritičkih stanica.
6. Pripravak za induciranje imunosnog odgovora kod sisavca, naznačen time što sadrži limfoidne stanice, kod kojih je ekspresija antigena raka odnosno testisa kemijski inducirana metiliranjem DNA ili acetiliranjem histona nakon aktivacije uz pomoć normalnih zrelih dendritičkih stanica koje ne sadrže antigene na koje treba usmjeriti imunosni odgovor kojeg će se inducirati.
7. Pripravak u skladu s patentnim zahtjevom 10, naznačen time što su limfoidne stanice limfociti, po mogućnosti limfociti iz periferne krvi.
8. Pripravak u skladu s patentnim zahtjevom 6 ili 7, naznačen time što se antigene inducira tijekom logaritamske faze proliferacije.
9. Pripravak u skladu s bilo kojim od patentnih zahtjeva 7 do 8, naznačen time što limfociti koji eksprimiraju antigene uključuju stanice CD4+.
10. Pripravak u skladu s bilo kojim od patentnih zahtjeva 6 do 9, naznačen time što se demetiliranje DNA sastoji u obradi 5-aza-2-deoksicitidinom, ili inhibitorom deacetiliranja histona.
11. Cjepivo za profilaktičko ili terapijsko liječenje, naznačeno time što sadrži pripravak u skladu s bilo kojim od patentnih zahtjeva 6 do 10 i prihvatljivu podlogu.
12. Upotreba pripravka u skladu s bilo kojim od patentnih zahtjeva 6 do 10, naznačena time što je navedeni pripravak namijenjen pripravi cjepiva za stimuliranje imunosnog odgovora na tumorski antigeni.
13. Upotreba pripravka u skladu s bilo kojim od patentnih zahtjeva 6 do 10, naznačena time što je navedeni pripravak sadrži antigenski prezentirajuće stanice za aktiviranje citotoksičnih T-limfocita.
14. Postupak dobivanja tumorski specifičnih citotoksičnih T-limfocita CD8+, naznačen time što se sastoji u aktiviranju T-limfocita pripravkom u skladu s bilo kojim od patentnih zahtjeva 6 do 10, kao antigenski prezentirajućih stanica.
15. Upotreba tumorski specifičnih citotoksičnih T-limfocita CD8+, dobivenih postupkom u skladu s patentnim zahtjevom 14, naznačena time što su navedeni limfociti namijenjeni pripravi farmaceutskog pripravka za adoptivnu imunoterapiju T-stanicama.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0700058.1A GB0700058D0 (en) | 2007-01-03 | 2007-01-03 | Anti-tumor vaccine based on normal cells |
PCT/EP2008/050050 WO2008081035A1 (en) | 2007-01-03 | 2008-01-03 | Anti-tumor vaccine derived from normal chemically modified cells |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20110899T1 true HRP20110899T1 (hr) | 2011-12-31 |
Family
ID=37759205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20110899T HRP20110899T1 (hr) | 2007-01-03 | 2011-11-30 | Protutumorsko cjepivo dobiveno iz normalnih, kemijski modificiranih stanica cd4+ |
Country Status (14)
Country | Link |
---|---|
US (2) | US10023839B2 (hr) |
EP (1) | EP2102331B1 (hr) |
JP (1) | JP5452231B2 (hr) |
AT (1) | ATE522600T1 (hr) |
AU (1) | AU2008203730B2 (hr) |
CY (1) | CY1112668T1 (hr) |
DK (1) | DK2102331T3 (hr) |
ES (1) | ES2372713T3 (hr) |
GB (1) | GB0700058D0 (hr) |
HR (1) | HRP20110899T1 (hr) |
PL (1) | PL2102331T3 (hr) |
PT (1) | PT2102331E (hr) |
SI (1) | SI2102331T1 (hr) |
WO (1) | WO2008081035A1 (hr) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA011421B1 (ru) * | 2008-08-26 | 2009-02-27 | Петр Генриевич ЛОХОВ | Способ получения противоопухолевой вакцины |
US8586359B2 (en) * | 2009-07-28 | 2013-11-19 | Promising Furture, LLC | Compositions and methods of preparing alloreactive cytotoxic T cells |
US8666674B2 (en) | 2009-07-28 | 2014-03-04 | Promising Future, Llc | Pairing processes for preparing reactive cytotoxic T cells |
EP2494038B1 (en) | 2009-10-27 | 2019-06-26 | Immunicum AB | Method for proliferation of antigen-specific t cells |
GB201013443D0 (en) | 2010-08-11 | 2010-09-22 | Cytovac As | Compositions and methods for producing dendritic cells |
US10426740B1 (en) | 2010-08-18 | 2019-10-01 | Avm Biotechnology, Llc | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
IL295224A (en) | 2015-05-28 | 2022-10-01 | Kite Pharma Inc | Methods for training patients for t-cell therapy |
MA45281A (fr) | 2015-05-28 | 2018-04-11 | Kite Pharma Inc | Procédés de diagnostic pour thérapie par lymphocytes t |
CN108366995A (zh) | 2015-10-20 | 2018-08-03 | 凯德药业股份有限公司 | 制备用于t细胞疗法的t细胞的方法 |
WO2017173384A1 (en) | 2016-04-01 | 2017-10-05 | Kite Pharma, Inc. | Chimeric receptors and methods of use thereof |
KR102522622B1 (ko) | 2016-04-01 | 2023-04-18 | 카이트 파마 인코포레이티드 | Bcma 결합 분자 및 그의 사용 방법 |
SG11201808411RA (en) | 2016-04-01 | 2018-10-30 | Kite Pharma Inc | Chimeric antigen and t cell receptors and methods of use |
US11046775B2 (en) | 2017-02-14 | 2021-06-29 | Kite Pharma, Inc. | CD70 binding molecules and methods of use thereof |
TW201837175A (zh) | 2017-03-13 | 2018-10-16 | 美商凱特製藥公司 | 用於黑色素瘤之嵌合抗原受體及其用途 |
JP6748221B2 (ja) | 2017-04-01 | 2020-08-26 | エーブイエム・バイオテクノロジー・エルエルシー | 細胞免疫療法前の細胞毒性プレコンディショニングの代替 |
WO2018187332A1 (en) | 2017-04-03 | 2018-10-11 | Kite Pharma, Inc. | Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells |
JOP20180042A1 (ar) | 2017-04-24 | 2019-01-30 | Kite Pharma Inc | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام |
WO2018218105A1 (en) | 2017-05-26 | 2018-11-29 | Kite Pharma, Inc. | Methods of making and using embryonic mesenchymal progenitor cells |
CN114533863A (zh) | 2017-09-15 | 2022-05-27 | 凯德药业股份有限公司 | 用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的方法和系统 |
WO2019060695A1 (en) | 2017-09-22 | 2019-03-28 | Kite Pharma, Inc. | CHIMERIC POLYPEPTIDES AND USES THEREOF |
CN111479613A (zh) | 2017-10-18 | 2020-07-31 | 凯德药业股份有限公司 | 施用嵌合抗原受体免疫疗法的方法 |
US11390655B2 (en) | 2017-11-16 | 2022-07-19 | Kite Pharma, Inc. | Modified chimeric antigen receptors and methods of use |
KR20200110356A (ko) | 2018-01-15 | 2020-09-23 | 화이자 인코포레이티드 | 키메라 항원 수용체 면역요법을 4-1bb 효능제와 조합하여 투여하는 방법 |
US20200390814A1 (en) | 2018-02-02 | 2020-12-17 | Arizona Board Of Regents On Behalf Of Arizona State University | Dna-chimeric antigen receptor t cells for immunotherapy |
WO2019161271A1 (en) | 2018-02-16 | 2019-08-22 | Kite Pharma, Inc. | Modified pluripotent stem cells and methods of making and use |
CN112218888A (zh) | 2018-04-12 | 2021-01-12 | 凯德药业股份有限公司 | 使用肿瘤微环境的特征的嵌合受体t细胞治疗 |
SG11202011541SA (en) | 2018-06-01 | 2020-12-30 | Kite Pharma Inc | Chimeric antigen receptor t cell therapy |
EP3810780A1 (en) | 2018-06-22 | 2021-04-28 | Kite Pharma Eu B.V. | Compositions and methods for making engineered t cells |
US20200038442A1 (en) | 2018-08-02 | 2020-02-06 | Kite Pharma, Inc. | Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof |
EP3488851A1 (en) | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
EP3632446B3 (en) | 2018-10-03 | 2024-01-24 | AVM Biotechnology, LLC | Immunoablative therapies |
US11793834B2 (en) | 2018-12-12 | 2023-10-24 | Kite Pharma, Inc. | Chimeric antigen and T cell receptors and methods of use |
EP3953454A1 (en) | 2019-04-12 | 2022-02-16 | CytoVac A/S | Method for preparation of cancer/testis antigen-specific t-cells |
BR112021021996A2 (pt) | 2019-05-03 | 2022-01-11 | Kite Pharma Inc | Métodos para administração de imunoterapia com receptores de antígeno quimérico |
BR112021025735A2 (pt) | 2019-06-21 | 2022-03-08 | Kite Pharma Inc | Receptores de tgf-ss e métodos de uso |
CN114341348A (zh) | 2019-09-03 | 2022-04-12 | 艾洛基治疗公司 | 制备用于t细胞疗法的t细胞的方法 |
WO2021260675A1 (en) | 2020-06-24 | 2021-12-30 | Yeda Research And Development Co. Ltd. | Agents for sensitizing solid tumors to treatment |
JP2023538012A (ja) | 2020-08-14 | 2023-09-06 | カイト ファーマ インコーポレイテッド | 免疫細胞機能の改善 |
EP4204545A2 (en) | 2020-08-25 | 2023-07-05 | Kite Pharma, Inc. | T cells with improved functionality |
WO2022093925A1 (en) | 2020-10-28 | 2022-05-05 | Kite Pharma, Inc. | Flow cytometric method for characterization of t-cell impurities |
EP4267623A1 (en) | 2020-12-24 | 2023-11-01 | Kite Pharma, Inc. | Prostate cancer chimeric antigen receptors |
CN116917737A (zh) | 2021-01-10 | 2023-10-20 | 凯德药业股份有限公司 | T细胞疗法 |
WO2022157288A1 (en) | 2021-01-21 | 2022-07-28 | Cytovac A/S | Method for t-cell expansion and related medical applications |
TW202241469A (zh) | 2021-02-20 | 2022-11-01 | 美商凱特製藥公司 | 免疫療法 |
US20220289815A1 (en) | 2021-03-11 | 2022-09-15 | Kite Pharma, Inc. | Immune cell function |
KR20230172002A (ko) | 2021-04-16 | 2023-12-21 | 카이트 파마 인코포레이티드 | Taci/bcma 이중 결합 분자 |
US20220336087A1 (en) | 2021-04-16 | 2022-10-20 | Kite Pharma, Inc. | Methods and systems for scheduling a patient-specific immunotherapy procedure |
US20220378830A1 (en) | 2021-05-14 | 2022-12-01 | Kite Pharma, Inc. | Chimeric antigen receptor t cell therapy |
EP4347638A2 (en) | 2021-05-24 | 2024-04-10 | Kite Pharma, Inc. | Nkg2d-based chimeric antgen receptor |
AU2022291365A1 (en) | 2021-06-08 | 2024-01-18 | Kite Pharma, Inc. | Gpc3 binding molecules |
WO2022269019A1 (en) | 2021-06-25 | 2022-12-29 | Cytovac A/S | Method for preparation of cytotoxic t lymphocytes with broad tumour-specific reactivity and characteristics of early differentiation cells |
WO2023278553A1 (en) | 2021-07-01 | 2023-01-05 | Kite Pharma, Inc. | Closed-system and method for autologous and allogeneic cell therapy manufacturing |
US20230103457A1 (en) | 2021-07-02 | 2023-04-06 | Kite Pharma, Inc. | Method for identifying variants in gene products from gene constructs used in cell therapy applications |
EP4376876A1 (en) | 2021-07-26 | 2024-06-05 | Kite Pharma, Inc. | Split chimeric antigen receptors and methods of use |
CA3225306A1 (en) | 2021-07-30 | 2023-02-02 | Kite Pharma, Inc. | Monitoring and management of cell therapy-induced toxicities |
CN118103403A (zh) | 2021-10-18 | 2024-05-28 | 凯德药业股份有限公司 | 嵌合抗原受体的信号传导结构域 |
WO2023159001A1 (en) | 2022-02-15 | 2023-08-24 | Kite Pharma, Inc. | Predicting adverse events from immunotherapy |
WO2023247324A1 (en) | 2022-06-24 | 2023-12-28 | Cytovac A/S | Novel combination treatment with adoptive cellular therapy |
WO2024044670A1 (en) | 2022-08-26 | 2024-02-29 | Kite Pharma, Inc. | Improving immune cell function |
WO2024092152A1 (en) | 2022-10-28 | 2024-05-02 | Kite Pharma, Inc. | Improving efficacy and durable response of immunotherapy |
US20240158869A1 (en) | 2022-10-28 | 2024-05-16 | Kite Pharma, Inc. | Factors for optimizing immunotherapy |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003012085A1 (en) * | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
-
2007
- 2007-01-03 GB GBGB0700058.1A patent/GB0700058D0/en not_active Ceased
-
2008
- 2008-01-03 US US12/522,048 patent/US10023839B2/en active Active
- 2008-01-03 EP EP08701232A patent/EP2102331B1/en active Active
- 2008-01-03 DK DK08701232.4T patent/DK2102331T3/da active
- 2008-01-03 PT PT08701232T patent/PT2102331E/pt unknown
- 2008-01-03 ES ES08701232T patent/ES2372713T3/es active Active
- 2008-01-03 SI SI200830447T patent/SI2102331T1/sl unknown
- 2008-01-03 AT AT08701232T patent/ATE522600T1/de active
- 2008-01-03 AU AU2008203730A patent/AU2008203730B2/en not_active Ceased
- 2008-01-03 JP JP2009544412A patent/JP5452231B2/ja not_active Expired - Fee Related
- 2008-01-03 PL PL08701232T patent/PL2102331T3/pl unknown
- 2008-01-03 WO PCT/EP2008/050050 patent/WO2008081035A1/en active Application Filing
-
2011
- 2011-11-17 CY CY20111101112T patent/CY1112668T1/el unknown
- 2011-11-30 HR HR20110899T patent/HRP20110899T1/hr unknown
-
2017
- 2017-09-18 US US15/707,474 patent/US20180036397A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP5452231B2 (ja) | 2014-03-26 |
EP2102331B1 (en) | 2011-08-31 |
SI2102331T1 (sl) | 2012-01-31 |
AU2008203730A1 (en) | 2008-07-10 |
US10023839B2 (en) | 2018-07-17 |
ES2372713T3 (es) | 2012-01-25 |
US20180036397A1 (en) | 2018-02-08 |
GB0700058D0 (en) | 2007-02-07 |
DK2102331T3 (da) | 2011-10-17 |
WO2008081035A1 (en) | 2008-07-10 |
PL2102331T3 (pl) | 2012-01-31 |
AU2008203730B2 (en) | 2013-11-07 |
US20100092498A1 (en) | 2010-04-15 |
CY1112668T1 (el) | 2016-02-10 |
PT2102331E (pt) | 2011-12-19 |
EP2102331A1 (en) | 2009-09-23 |
ATE522600T1 (de) | 2011-09-15 |
JP2010514455A (ja) | 2010-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20110899T1 (hr) | Protutumorsko cjepivo dobiveno iz normalnih, kemijski modificiranih stanica cd4+ | |
JP2010514455A5 (hr) | ||
Sabado et al. | Dendritic cell-based immunotherapy | |
EP2494038B1 (en) | Method for proliferation of antigen-specific t cells | |
Galluzzi et al. | Trial watch: Dendritic cell-based interventions for cancer therapy | |
Wennhold et al. | CD40-activated B cells induce anti-tumor immunity in vivo | |
Yao et al. | Dendritic cells pulsed with leukemia cell-derived exosomes more efficiently induce antileukemic immunities | |
JP2013177430A5 (hr) | ||
JP2013535218A5 (hr) | ||
Huarte et al. | Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma | |
Abraham et al. | Gene-modified dendritic cell vaccines for cancer | |
Shao et al. | Artificial antigen-presenting cells are superior to dendritic cells at inducing antigen-specific cytotoxic T lymphocytes | |
Batista-Duharte et al. | Regulatory T cells and vaccine effectiveness in older adults. Challenges and prospects | |
RU2728592C1 (ru) | Способ стимуляции презентирующей активности дендритных клеток | |
Gritzapis et al. | Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice | |
Shao et al. | Engineered cells for costimulatory enhancement combined with IL-21 enhance the generation of PD-1-disrupted CTLs for adoptive immunotherapy | |
Millard et al. | Dendritic cell KLH loading requirements for efficient CD4+ T-cell priming and help to peptide-specific cytotoxic T-cell response, in view of potential use in cancer vaccines | |
Saha et al. | Stimulatory effects of CpG oligodeoxynucleotide on dendritic cell‐based immunotherapy of colon cancer in CEA/HLA‐A2 transgenic mice | |
Cao et al. | Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma | |
PT1224264E (pt) | Modificação de células imunogénicas | |
Al Saihati | Overview of Dendritic Cell Vaccines as Effective Approaches in Cancer Immunotherapy. | |
He et al. | Antigen epitope-expressing cytokines for DNA immunization | |
WO2017139742A1 (en) | Placental compositions for stimulation of immunity to pd-l1 | |
Yun et al. | Generation of antigen-specific cytotoxic T lymphocytes with activated B cells | |
Peng et al. | EWS/FLI-l peptide-pulsed dendritic cells induces the antitumor immunity in a murine Ewing's sarcoma cell model |